129 related articles for article (PubMed ID: 37183823)
21. LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors.
Tao T; Shi H; Mariani L; Abraham BJ; Durbin AD; Zimmerman MW; Powers JT; Missios P; Ross KN; Perez-Atayde AR; Bulyk ML; Young RA; Daley GQ; Look AT
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16516-16526. PubMed ID: 32601179
[TBL] [Abstract][Full Text] [Related]
22. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.
Hsu CL; Chang HY; Chang JY; Hsu WM; Huang HC; Juan HF
Oncotarget; 2016 Jun; 7(24):36293-36310. PubMed ID: 27167114
[TBL] [Abstract][Full Text] [Related]
23. Collaborative ISL1/GATA3 interaction in controlling neuroblastoma oncogenic pathways overlapping with but distinct from MYCN.
Zhang Q; Zhang Q; Jiang X; Ye Y; Liao H; Zhu F; Yan J; Luo L; Tian L; Jiang C; Chen Y; Liang X; Sun Y
Theranostics; 2019; 9(4):986-1000. PubMed ID: 30867811
[No Abstract] [Full Text] [Related]
24. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.
Duijkers FA; Meijerink JP; Pieters R; van Noesel MM
Gene; 2013 May; 521(1):62-8. PubMed ID: 23523856
[TBL] [Abstract][Full Text] [Related]
26. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in
Feriancikova B; Feglarova T; Krskova L; Eckschlager T; Vicha A; Hrabeta J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806217
[TBL] [Abstract][Full Text] [Related]
27. Genetic Predisposition to Neuroblastoma Results from a Regulatory Polymorphism that Promotes the Adrenergic Cell State.
Weichert-Leahey N; Shi H; Tao T; Oldridge DA; Durbin AD; Abraham BJ; Zimmerman MW; Zhu S; Wood AC; Reyon D; Joung JK; Young RA; Diskin SJ; Maris JM; Look AT
bioRxiv; 2023 Mar; ():. PubMed ID: 36909587
[TBL] [Abstract][Full Text] [Related]
28. TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets.
Decaesteker B; Denecker G; Van Neste C; Dolman EM; Van Loocke W; Gartlgruber M; Nunes C; De Vloed F; Depuydt P; Verboom K; Rombaut D; Loontiens S; De Wyn J; Kholosy WM; Koopmans B; Essing AHW; Herrmann C; Dreidax D; Durinck K; Deforce D; Van Nieuwerburgh F; Henssen A; Versteeg R; Boeva V; Schleiermacher G; van Nes J; Mestdagh P; Vanhauwaert S; Schulte JH; Westermann F; Molenaar JJ; De Preter K; Speleman F
Nat Commun; 2018 Nov; 9(1):4866. PubMed ID: 30451831
[TBL] [Abstract][Full Text] [Related]
29. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
[TBL] [Abstract][Full Text] [Related]
30. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
31. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
[TBL] [Abstract][Full Text] [Related]
32. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
33. Unraveling Neuroblastoma Pathogenesis with the Zebrafish.
Dankert EN; Look AT; Zhu S
Cell Cycle; 2018; 17(4):395-396. PubMed ID: 29231124
[No Abstract] [Full Text] [Related]
34.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract][Full Text] [Related]
35. Integrative genomics identifies LMO1 as a neuroblastoma oncogene.
Wang K; Diskin SJ; Zhang H; Attiyeh EF; Winter C; Hou C; Schnepp RW; Diamond M; Bosse K; Mayes PA; Glessner J; Kim C; Frackelton E; Garris M; Wang Q; Glaberson W; Chiavacci R; Nguyen L; Jagannathan J; Saeki N; Sasaki H; Grant SF; Iolascon A; Mosse YP; Cole KA; Li H; Devoto M; McGrady PW; London WB; Capasso M; Rahman N; Hakonarson H; Maris JM
Nature; 2011 Jan; 469(7329):216-20. PubMed ID: 21124317
[TBL] [Abstract][Full Text] [Related]
36. A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.
Li HL; Dong LL; Jin MJ; Li QY; Wang X; Jia MQ; Song J; Zhang SY; Yuan S
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770809
[TBL] [Abstract][Full Text] [Related]
37. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
38. Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification.
Mitchell CB; O'Neill GM
Cell Adh Migr; 2017 Jan; 11(1):68-79. PubMed ID: 27224546
[TBL] [Abstract][Full Text] [Related]
39. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
40. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]